Neprilysin Inhibitors: Emerging Therapy for Heart Failure

Literature Cited

1. Braunwald E. 1.  2015. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J. Am. Coll. Cardiol. 65:1029–41 [Google Scholar]
2. Vardeny O, Miller R, Solomon SD. 2.  2014. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC: Heart Fail 2:663–70 [Google Scholar]
3. Rouleau JL, Pfeffer MA, Stewart DJ. 3.  et al. 2000. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 356:615–20 [Google Scholar]
4. Packer M, Califf RM, Konstam MA. 4.  et al. 2002. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106:920–26 [Google Scholar]
5. Kostis JB, Packer M, Black HR. 5.  et al. 2004. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am. J. Hypertens. 17:103–11 [Google Scholar]
6. Solomon SD, Zile M, Pieske B. 6.  et al. 2012. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380:1387–95 [Google Scholar]
7. McMurray JJ, Packer M, Desai AS. 7.  et al. 2014. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371:993–1004 [Google Scholar]
8. 8. The CONSENSUS Trial Study Group 1987. Effects of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med. 316:1429–35 [Google Scholar]
9. 9. SOLVD Investigators 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325:293–302 [Google Scholar]
10. Pitt B, Poole-Wilson PA, Segal R. 10.  et al. 2000. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–87 [Google Scholar]
11. Cohn JN, Tognoni G. 11.  2001. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345:1667–75 [Google Scholar]
12. Granger CB, McMurray JJV, Yusuf S. 12.  et al. 2003. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–76 [Google Scholar]
13. Mills J, Vardeny O. 13.  2015. The role of neprilysin inhibitors in cardiovascular disease. Curr. Heart Fail. Rep. 12:389–94 [Google Scholar]
14. Filippatos G, Farmakis D, Parissis J, Lekakis J. 14.  2015. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Med 13:35 [Google Scholar]
15. Judge P, Haynes R, Landray MJ, Baigent C. 15.  2015. Neprilysin inhibition in chronic kidney disease. Nephrol. Dial. Transplant. 30:738–43 [Google Scholar]
16. Ruggenenti P, Remuzzi G. 16.  2015. Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?. Eur. J. Heart Fail. 17:468–71 [Google Scholar]
17. Langenickel T, Dole W. 17.  2013. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov. Today Ther. Strateg. 9:4e131–e139 [Google Scholar]
18. Martinez-Rumayor A, Richards AM, Burnett JC, Jr Januzzi JL. 18.  2008. Biology of the natriuretic peptides. Am. J. Cardiol. 101:3–8 [Google Scholar]
19. Packer M, McMurray JJ, Desai AS. 19.  et al. 2015. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54–61 [Google Scholar]
20. Hubers SA, Brown NJ. 20.  2016. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation 133:1115–24 [Google Scholar]
21. Querfurth HW, LaFerla FM. 21.  2010. Alzheimer's disease. N. Engl. J. Med. 362:329–44 [Google Scholar]
22. Ollendorf D, Sandhu A, Chapman R. 22.  et al. 2015. CardioMEMs HF Systems (St. Jude Medical) and sacubitril/valsartan (Entresto, Novartis) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks. Calif. Technol. Assess. For. https://icer-review.org/topic/congestive-heart-failure [Google Scholar]
23. Feldman AM, Haller JA, DeKosky ST. 23.  2016. Valsartan/sacubitril for heart failure: reconciling disparities between preclinical and clinical investigations. JAMA 315:25–26 [Google Scholar]
24. Grainger D. 24.  2015. Is the superiority of Entresto just an illusion?. Forbes Sep. 14. http://www.forbes.com/sites/davidgrainger/2015/09/14/is-the-superiority-of-entresto-just-an-illusion/#191ec4670a4f [Google Scholar]